Halozyme’s human enzyme proves safe in clinical trial
“Halozyme Therapeutics has received positive data from a clinical trial evaluating the safety of human hyaluronidase in healthy volunteers. Researchers found an absence of allergic reactions to the enzyme which produced less discomfort on administration than the control substance.
“The double-blinded clinical study compared recombinant human hyaluronidase (rHuPH20) to a saline control in 100 healthy human volunteers. These volunteers were injected intradermally with rHuPH20 in one forearm and saline control in the other forearm, and evaluated for allergic responses and injection site side effects.”
Read more at Halozyme’s human enzyme proves safe in clinical trial
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax